Celularity Management
Management criteria checks 3/4
Celularity's CEO is Bob Hariri, appointed in Jul 2021, has a tenure of 4.42 years. total yearly compensation is $848.96K, comprised of 21.1% salary and 78.9% bonuses, including company stock and options. directly owns 10.09% of the company’s shares, worth $3.77M. The average tenure of the management team and the board of directors is 4.2 years and 3.7 years respectively.
Key information
Bob Hariri
Chief executive officer
US$849.0k
Total compensation
| CEO salary percentage | 21.10% |
| CEO tenure | 4.4yrs |
| CEO ownership | 10.1% |
| Management average tenure | 4.2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding
Dec 15
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 59%
Aug 14Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry
Feb 21Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$81m |
| Jun 30 2025 | n/a | n/a | -US$74m |
| Mar 31 2025 | n/a | n/a | -US$56m |
| Dec 31 2024 | US$849k | US$179k | -US$58m |
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$154m |
| Dec 31 2023 | US$1m | US$1m | -US$196m |
| Sep 30 2023 | n/a | n/a | -US$181m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | US$13m |
| Dec 31 2022 | US$5m | US$1m | US$14m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | US$31m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$22m | US$1m | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$188m |
| Mar 31 2021 | n/a | n/a | -US$260m |
| Dec 31 2020 | US$3m | US$1m | -US$208m |
Compensation vs Market: Bob's total compensation ($USD848.96K) is above average for companies of similar size in the US market ($USD575.90K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Hariri (66 yo)
Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.4yrs | US$848.96k | 10.09% $ 3.8m | |
| Senior EVP | 7.9yrs | US$517.01k | 0.10% $ 38.4k | |
| Senior VP of Finance & Interim CFO | less than a year | no data | no data | |
| SVP of Investor Relations | no data | no data | no data | |
| President of Degenerative Diseases | 4.4yrs | no data | 0.031% $ 11.8k | |
| Senior Vice President of Clinical Dev. Immunology & Drug Safety | 3.9yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2.5yrs | no data | no data | |
| Treasurer | no data | no data | no data |
Experienced Management: CELU's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.4yrs | US$848.96k | 10.09% $ 3.8m | |
| Independent Director | 3.5yrs | US$365.00k | 1.29% $ 481.8k | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 4.4yrs | US$353.00k | 0.88% $ 328.4k | |
| Independent Director | 2.3yrs | US$348.75k | 0.39% $ 147.6k | |
| Co-Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.013% $ 4.9k |
Experienced Board: CELU's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 08:21 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Thomas Shrader | BTIG |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |